<DOC>
	<DOCNO>NCT00003042</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase II trial study well chemotherapy stem cell transplantation work treat patient stage IIIB breast cancer .</brief_summary>
	<brief_title>Chemotherapy Stem Cell Transplantation Treating Patients With Stage IIIB Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness neoadjuvant dose intensive sequential chemotherapy , follow surgical resection , adjuvant therapy , tandem high dose chemotherapy stem cell rescue patient inflammatory stage IIIB breast cancer . - Determine clinical pathological remission rate ( complete , partial , overall ) follow neoadjuvant dose dependent sequential chemotherapy patient inflammatory stage IIIB breast cancer . - Determine relapse survival rate patient therapy . - Determine potential correlation inflammatory feature hereditary background . OUTLINE : Patients stratify accord 1 cycle neoadjuvant chemotherapy ( stratum 1 ) 1 cycle neoadjuvant chemotherapy and/or modify radical mastectomy ( stratum 2 ) . Patients stratum 1 receive doxorubicin IV 96 hour day 1-4 , 15-19 , 29-32 . Paclitaxel infuse 96 hour day 43-47 57-60 . Filgrastim ( G-CSF ) administer day 5-10 , 20-25 , 33-38 , 48-55 , 61-68 , beyond granulocyte count less 1000/mm^3 . A modified radical mastectomy perform day 70 80 . All stratum 1 stratum 2 patient receive paclitaxel IV 96 hour day 100-104 , cyclophosphamide IV day 121 . Filgrastim administer one dose day 105-110 day 122-127 high dose day 110-116 day 128-135 . Stem cell harvest patient day 113-116 day 132-135 . High-dose chemotherapy administer patient study . Course 1 start doxorubicin IV day -7 -3 . Paclitaxel IV administer 24 hour day -2 . Filgrastim administer IV day -1 continue granulocyte count great 1000/mm^3 3 day . Peripheral stem cell reinfused day 0 . Course 2 start 4-6 week start course 1 melphalan cisplatin infused day -11 . Filgrastim administer IV day -10 -6 . Melphalan cisplatin administer day -4 . Stem cell infuse day -3 day 0 . Filgrastim administer granulocyte count least 1000/mm^3 3 day . Radiation therapy start 4-7 week begin course 2 . Tamoxifen start within 2 week discharge follow course 2 patient hormone receptor positive tumor . Patients follow every 3 month two year annually next three year . PROJECTED ACCRUAL : Approximately 60 patient accrue , rate 15 per year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIB breast cancer dermal/epidermal invasion clinical feature inflammation , erythema , pain hypersensitivity , edema , thicken skin Diagnosis within past 6 month PATIENT CHARACTERISTICS : Age : 60 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL SGOT SGPT great 1.5 time upper limit normal Renal : Creatinine le 1.2 mg/dL Creatinine clearance least 80 mL/min No history hemorrhagic cystitis Cardiovascular : Left ventricular fraction least 55 % MUGA scan No previous valvular heart disease arrhythmia Pulmonary : FEV_1 least 60 % predict Room air pO_2 great 85 mmHg Room air pCO_2 great 43 mmHg DLCO least 60 % low limit predict value Other : No history malignant disease past 5 year , except squamous basal cell skin cancer stage I situ cervical cancer No organic CNS dysfunction Not pregnant No known potentially disable psychosocial history Not positive hepatitis B HIV PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Stratum 1 : No one cycle chemotherapy Stratum 2 : No great 225 mg/m^2 doxorubicin great 250 mg/m^2 paclitaxel previous chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiation leave chest wall Surgery : Modified radical mastectomy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>